期刊文献+

基层医院丙型病毒性肝炎筛查与控制情况的探讨

暂未订购
导出
摘要 目的了解基层医院对丙型病毒性肝炎筛查情况,探索早期筛查加以控制丙型肝炎的重要性。方法对2009年1月至2011年12月来院诊疗的患者丙型肝炎筛查和诊疗情况进行回顾性调查,抗-HCV检测应用酶联免疫法(ELISA),HCV-RNA采用PCR方法检测。结果 3年共检测丙型肝炎抗体7920例,抗-HCV阳性者共175例,阳性率2.21%,其中进行HCV-RNA检测者39例,阳性者36例,相对规范治疗的8例。结论注重基层医院丙型肝炎病毒筛查,提高医务人员对丙型肝炎的认知率,对抗-HCV阳性患者进行必要的指导和干预,有效地控制丙型肝炎的感染。
出处 《国际检验医学杂志》 CAS 2012年第15期1888-1889,共2页 International Journal of Laboratory Medicine
  • 相关文献

参考文献13

  • 1李玉林.病理学[M]北京:人民卫生出版社,2008177.
  • 2彭文伟.传染病学[M]北京:人民卫生出版社,200126.
  • 3Thomas DL,Seeff LB. Natural history of hepatitisC[J].ClinliverDis,2005,(03):383-398.doi:10.1016/j.cld.2005.05.003.
  • 4Ayyub MA,EI-Moursy SA,Khazindar AM. Successful treatment of chronic hepatitis C virus infection with peg-inter-feron alpha-2a and ribaverin in patients with sickle cell disease[J].Saudi Medical Journal,2009,(05):712-716.
  • 5徐潜,王卫华.综合医院中早期识别与控制丙型病毒性肝炎的探讨[J].中华医院感染学杂志,2011,21(17):3573-3575. 被引量:9
  • 6Yu ML,Chuang WL. Treatment of chronic hepatitis C in Asia:when East meets west[J].Gastroentrrol Hepatol,2009,(03):336-345.
  • 7Wasley A,Alter MJ. Epiderriology of hepatitis C:geographic differences and temporal trends[J].Serrin Liver Dis,2000,(01):11-16.
  • 8戚中田.丙型肝炎的致病机制及药物治疗[J].传染病信息,2010,23(4):196-199. 被引量:12
  • 9KimWR. The burden of hepatitis C in the United States[J].Hepatology,2002,(5 Suppl):S30-S34.doi:10.1016/j.jaci.2009.06.040.
  • 10Planas R,Balleste B,Alvarez MA. Natural history of decompen sated hepatitisC virus related cirrhosis,a study of 200 patients[J].Hepatology,2004,(02):126-128.

二级参考文献52

  • 1Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update[J]. Hepatology, 2009,49(4): 1335-1374.
  • 2McCaughan GW, Omata M, Amarapurkar D, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection[J]. J Gastroenterol Hepatol,2007,22(5): 615-633.
  • 3Gordon SC. Treatment of viral hepatitis-2001 [J]. Ann Med, 2001,33(6):385-390.
  • 4Pawlotsky JM. Treating hepatitis C in "difficult-to-treat" patients[J]. N Engl J Med, 2004,351 (5):422-423.
  • 5Fried MW, Jensen DM, Rodriguez-Torres M, et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin[J]. Hepatology,2008,48(4): 1033-1043.
  • 6Alberti A. What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? [J]. Liver Int,2009,29(Suppl 1):S15-S18.
  • 7Farnik H, Mihm U ,Zeuzem S. Optimal therapy in genotype 1 patients[J]. Liver Int, 2009,29(Suppl 1):S23-S30.
  • 8Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy[J]. Gastroenterology, 2009, 136(5):1618-1628.
  • 9Jensen DM, Marcellin P, Freilich B, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha 2b: a randomized trial[J]. Ann Intern Med, 2009,150(8):528-540.
  • 10McHutchison JG, Shiffman ML, Terrault N, et al. A phase 2b study of telaprevir with peginterferon-alfa-2a and ribavirin in hepatitis C genotype 1 null and partial responders and relapsers following a prior course of peginterferon-alfa- 2a/b and ribavirin therapy: PROVE3 interim resuhs[C/OL]// 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA, October 31- November 1, 2008. [2009-06-10]. http://www.natap.org/2008/ AASLD/AASLD_14.htm.

共引文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部